Market Overview

UPDATE: Oppenheimer Assumes Endo Health Solutions at Perform on Operational Restructuring

Share:
Related ENDP
UPDATE: Morgan Stanley Resumes Coverage On Endo International On Durable Growth And M&A Optionality
Analyst: Boston Scientific's Acquisition Is 'Strategically Sound'
DURECT's Endogenous Epigenomic Regulator DUR-928 - What You Need To Know (Seeking Alpha)

In a report published Friday, Oppenheimer analyst Akiva Felt assumed coverage on Endo Health Solutions (NASDAQ: ENDP) with a Perform rating.

In the report, Oppenheimer noted, “We are assuming coverage of Endo Health Solutions (ENDP) with a Perform rating. We remain on the sidelines as the company undergoes an operational restructuring prompted by the upcoming loss of revenues from three main assets (45% of total 2012 sales), by mid-2014. Given these circumstances, Endo expects to conduct 2-3 bolt-on acquisitions with an aggregate value as high as $1.5B over the next 12-18 months. While we are encouraged by these intentions, it may prove difficult to locate quality assets at a reasonable price. With ENDP shares up 48% YTD, we believe the stock is fairly valued at current levels. We would look to revisit our current thesis after gauging ENDP's initial execution of its restructuring plan.”

Endo Health Solutions closed on Thursday at $37.52.

Latest Ratings for ENDP

DateFirmActionFromTo
Mar 2015Morgan StanleyReinstatesOverweight
Mar 2015Canaccord GenuityMaintainsBuy
Mar 2015Keefe Bruyette & WoodsMaintainsOutperform

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Akiva Felt OppenheimerAnalyst Color Initiation Analyst Ratings

 

Related Articles (ENDP)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→